What is the share price of Viyash Scientific Ltd (VIYASH) today?
The share price of VIYASH as on 31st July 2026 is ₹252. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Viyash Scientific Ltd (VIYASH) share?
The past returns of Viyash Scientific Ltd (VIYASH) share are- Past 1 week: -0.45%
- Past 1 month: -9.87%
- Past 3 months: 23.69%
- Past 6 months: 24.96%
- Past 1 year: 46.54%
- Past 3 years: 166.95%
- Past 5 years: -12.64%
What are the peers or stocks similar to Viyash Scientific Ltd (VIYASH)?
The peers or stocks similar to Viyash Scientific Ltd (VIYASH) include:What is the market cap of Viyash Scientific Ltd (VIYASH) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Viyash Scientific Ltd (VIYASH) is ₹10998.87 Cr as of 31st July 2026.What is the 52 week high and low of Viyash Scientific Ltd (VIYASH) share?
The 52-week high of Viyash Scientific Ltd (VIYASH) is ₹298 and the 52-week low is ₹166.What is the PE and PB ratio of Viyash Scientific Ltd (VIYASH) stock?
The P/E (price-to-earnings) ratio of Viyash Scientific Ltd (VIYASH) is 62.04. The P/B (price-to-book) ratio is 3.53.Which sector does Viyash Scientific Ltd (VIYASH) belong to?
Viyash Scientific Ltd (VIYASH) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Viyash Scientific Ltd (VIYASH) shares?
You can directly buy Viyash Scientific Ltd (VIYASH) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Viyash Scientific Ltd
VIYASH Share Price
NSE₹252.000.04% (+0.10)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
VIYASH Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
VIYASH Performance & Key Metrics
VIYASH Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 68.84 | 3.53 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.85 | 6.02 | 0.50% |
100%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
VIYASH Company Profile
Viyash Scientific Ltd is an integrated pharmaceutical company operating globally with eight manufacturing facilities across India, Turkey, Brazil, Spain, and Germany, specializing in animal health APIs, finished dosage formulations, and analytical services for pharmaceutical, personal care, and nutraceutical sectors.
SUNPHARMA
PE Ratio
41.60
41.60
1Y Return
16.63%
16.63%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
90.07
90.07
1Y Return
36.90%
36.90%
Buy Reco %
82.14
82.14
CIPLA
PE Ratio
30.68
30.68
1Y Return
5.24%
5.24%
Buy Reco %
63.89
63.89
ZYDUSLIFE
PE Ratio
22.30
22.30
1Y Return
16.19%
16.19%
Buy Reco %
55.17
55.17
LUPIN
PE Ratio
20.71
20.71
1Y Return
25.19%
25.19%
Buy Reco %
55.56
55.56
VIYASH Sentiment Analysis
VIYASH Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
VIYASH Stock Summary · May 2026
Management framed the call as a clear financial turnaround, highlighting record quarterly and annual profitability. Q4 adjusted EBITDA topped INR 200 crore (up 64% QoQ) and FY26 adjusted EBITDA rose 59.6% to INR 702 crore with PAT for the year reaching INR 225 crore (a 1,324% year‑on‑year increase), driven by a product‑mix shift and operational improvements that lifted gross margin to roughly 54–55%. Leadership emphasized accelerating higher‑value formulations (which outgrew APIs), scaling animal‑health—notably companion‑animal R&D and Europe/India go‑to‑market plans—expanding CDMO offerings across three models, and completing merger integration to unlock rising synergies. They were candid about tensions: near‑term drag from pre‑operating R&D and capacity build costs, working‑capital seasonality with longer receivables and solvent constraints, and minority stakes that depress consolidated PAT, even as inventory and freight volatility were being managed. Near term, management expects gross margins to stay largely stable within a ±1–2% band, frames FY27 as a platform‑building year for companion animals, targets an ~15% medium‑term CAGR and internal run‑rate goals of ~INR 800–1,000 crore over the next 1–3 years.
VIYASH Stock Growth Drivers
VIYASH Stock Growth Drivers
9Financial Turnaround and Margin Expansion
The company delivered a clear financial turnaround with record quarterly and annual results: Q4 revenue
Stronger Balance Sheet, Deleveraging and Credit Upgrade
The company has materially deleveraged its balance sheet and reports healthy liquidity that supports both
VIYASH Stock Challenges
VIYASH Stock Challenges
7Delayed maturation of CDMO/NCG strategic initiatives
The company’s CDMO push and the NCG/first-area program are long-duration initiatives that have only just
Subsidiary ownership, disclosure gaps and consolidation uncertainty
Material ownership structures and incomplete segment disclosures create opacity and near-term profitability risk at the
VIYASH Forecast
VIYASH Forecasts
Price
Revenue
Earnings
VIYASH Share Price Forecast
VIYASH Share Price Forecast
2026
Current
₹252.00
Baseline
Forecast for Jul 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹252.00
Baseline
Forecast for Jul 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
VIYASH Company Revenue Forecast
VIYASH Company Revenue Forecast
2026
Current
₹3.46
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹3.46
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
VIYASH Stock EPS (Earnings Per Share) Forecast
VIYASH Stock EPS (Earnings Per Share) Forecast
2026
Current
₹5.16
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹5.16
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
VIYASH
VIYASH
Income
Balance Sheet
Cash Flow
Quarterly Normal View
VIYASH Income Statement
VIYASH Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 336.64 | 365.20 | 392.89 | 373.16 | 780.69 | 403.36 | 445.29 | 857.76 | 872.39 | 935.88 | ||||||||||
Operating & Other expenses | 307.11 | 333.64 | 348.26 | 333.87 | 677.18 | 355.80 | 390.48 | 678.77 | 724.04 | 735.71 | ||||||||||
EBITDA | 29.53 | 31.56 | 44.63 | 39.29 | 103.51 | 47.56 | 54.81 | 178.99 | 148.35 | 200.17 | ||||||||||
| Depreciation/Amortization | 15.46 | 16.48 | 16.25 | 17.10 | 58.39 | 16.12 | 15.13 | 59.11 | 58.53 | 60.41 | ||||||||||
| PBIT | 14.07 | 15.08 | 28.38 | 22.19 | 45.12 | 31.44 | 39.68 | 119.88 | 89.82 | 139.76 | ||||||||||
| Interest & Other Items | 12.58 | 12.44 | 16.38 | 14.29 | 20.64 | 15.13 | 14.16 | 17.51 | 16.75 | 14.52 | ||||||||||
| PBT | 1.49 | 2.64 | 12.00 | 7.90 | 24.48 | 16.31 | 25.52 | 102.37 | 73.07 | 125.24 | ||||||||||
| Taxes & Other Items | -6.78 | 3.56 | 5.49 | 5.29 | -20.13 | 6.99 | 11.21 | 47.46 | 34.63 | 73.13 | ||||||||||
| Net Income | 8.27 | -0.92 | 6.51 | 2.61 | 44.61 | 9.32 | 14.31 | 54.91 | 38.44 | 52.11 | ||||||||||
| EPS | 0.33 | -0.04 | 0.26 | 0.11 | 1.04 | 0.37 | 0.57 | 1.28 | 0.89 | 1.20 |
VIYASH Company Updates
VIYASH Stock Peers
VIYASH Past Performance & Peer Comparison
VIYASH Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Viyash Scientific Ltd | 62.04 | 3.53 | — |
| Sun Pharmaceutical Industries Ltd | 41.60 | 5.69 | 0.80% |
| Torrent Pharmaceuticals Ltd | 90.07 | 11.08 | 0.66% |
| Cipla Ltd | 30.68 | 3.45 | 0.88% |
VIYASH Stock Price Comparison
Compare VIYASH with any stock or ETFCompare VIYASH with any stock or ETF
VIYASH
VIYASH Holdings
VIYASH Shareholdings
VIYASH Promoter Holdings Trend
VIYASH Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
VIYASH Institutional Holdings Trend
VIYASH Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has increased by 1.56%
VIYASH Shareholding Pattern
VIYASH Shareholding Pattern
VIYASH Shareholding History
VIYASH Shareholding History
Foreign Institutions
Mutual Funds Invested in VIYASH
Mutual Funds Invested in VIYASH
No mutual funds holding trends are available
Top 5 Mutual Funds holding Viyash Scientific Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.8306% | Percentage of the fund’s portfolio invested in the stock 0.95% | Change in the portfolio weight of the stock over the last 3 months -0.75% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 44/133 (-3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2567% | Percentage of the fund’s portfolio invested in the stock 2.32% | Change in the portfolio weight of the stock over the last 3 months 0.42% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 18/45 (+5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1069% | Percentage of the fund’s portfolio invested in the stock 0.48% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 142/255 (+4) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing VIYASH stock
smallcases containing VIYASH stock
Looks like this stock is not in any smallcase yet.
VIYASH Events
VIYASH Events
VIYASH Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VIYASH has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
VIYASH Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VIYASH has not given any dividends in last 5 years
VIYASH Upcoming Dividends
VIYASH Upcoming Dividends
No upcoming dividends are available
VIYASH Past Dividends
VIYASH Past Dividends
Cash Dividend
Ex DateEx DateSep 8, 2021
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateAug 21, 2019
Final
Final | Div/Share: ₹0.20
Dividend/Share
₹0.20
Ex DateEx Date
Aug 21, 2019
Cash Dividend
Ex DateEx DateNov 20, 2017
Interim
Interim | Div/Share: ₹0.20
Dividend/Share
₹0.20
Ex DateEx Date
Nov 20, 2017
Cash Dividend
Ex DateEx DateSep 16, 2011
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 16, 2011
Cash Dividend
Ex DateEx DateSep 23, 2010
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 23, 2010
VIYASH Stock News & Opinions
VIYASH Stock News & Opinions
Articles & Videos
Corporate
Corporate
Viyash Scientific to hold AGMViyash Scientific announced that the 41th Annual General Meeting(AGM) of the company will be held on 11 August 2026.
2 weeks agoCapital Market - Live
Corporate
Corporate
Viyash Scientific to acquire Milan-based pet care company BioForLifeViyash Scientific (Viyash), through its wholly owned subsidiary Alivira Animal Health (Alivira), has signed a binding agreement to acquire 100% stake in BioForLife Italia S.r.l. (BFL), a leading pet care company based in Milan, Italy. The acquisition, for a cash consideration of Rs 188 crore is expected to close in Q2 FY27. The transaction represents a significant step in Viyash's strategy to capitalize on the mega-trend of a growing Companion Animal Health Generics market. It expands Alivira's global Companion Animal Health business and strengthens its presence in the European pet care market.
1 month agoCapital Market - Live
Spotlight
Spotlight
Viyash Scientific rises after subsidiary inks Rs 188-crore deal to acquire Italy's BioForLifeThe acquisition, valued at approximately Rs 188 crore in cash, is expected to be completed in the second quarter of FY27. The transaction marks a significant step in Viyash Scientific's strategy to capitalize on the rapidly growing global companion animal health generics market. It is expected to strengthen Alivira's position in the European pet care sector and expand its global companion animal health business. According to the company, Italy ranks among the five largest animal health markets in Europe, with companion animal care emerging as the fastest-growing segment. Growth is being driven by increasing pet ownership, rising pet humanization trends, and higher spending on preventive and specialized veterinary care. BioForLife specializes in the development, commercialization, and distribution of pet care products. The company has built a strong presence in nutritional supplements, pharmaceuticals, and rapid diagnostic tests, while also expanding into high-growth segments such as dermatology and ophthalmology. Through its established sales network, BioForLife serves more than 80% of veterinary clinics across Italy. The acquisition is expected to provide a platform for launching new products from Alivira's pipeline in Italy, while simultaneously providing opportunities to expand the BFL range to other markets in the Alivira group located in Europe, Middle East, Asia and Latam. Dr. Haribabu Bodeputi, Managing Director and Group CEO, Viyash Scientific, said, This acquisition represents another important step in our strategy to build a leading global companion animal health business. BioForLife provides us with an established platform in Italy, one of Europe's most attractive pet care markets, while strengthening our presence across the region. The combination of BioForLife's commercial reach and Alivira's product development capabilities creates a compelling opportunity to accelerate growth, expand our companion animal portfolio and deliver greater value to veterinarians, pet owners and partners across markets. We also see meaningful opportunities to introduce innovative products into India and other geographies through our global reach. This investment reflects our continued commitment to sustainable growth, strategic expansion and long-term value creation. Sequent Scientific p is mainly engaged in the business of veterinary healthcare. The company's consolidated net profit surged 459.1% year on year to Rs 52.11 crore, while revenue from operations jumped 129% to Rs 919.96 crore in Q4 FY26 from Q4 FY25. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Earnings
Viyash Scientific consolidated net profit rises 459.12% in the March 2026 quarterNet profit of Viyash Scientific rose 459.12% to Rs 52.11 crore in the quarter ended March 2026 as against Rs 9.32 crore during the previous quarter ended March 2025. Sales rose 129.02% to Rs 919.96 crore in the quarter ended March 2026 as against Rs 401.70 crore during the previous quarter ended March 2025. For the full year,net profit rose 663.48% to Rs 177.28 crore in the year ended March 2026 as against Rs 23.22 crore during the previous year ended March 2025. Sales rose 13.75% to Rs 3420.31 crore in the year ended March 2026 as against Rs 3006.84 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales919.96401.70 129 3420.313006.84 14 OPM %20.0311.51 -19.0812.87 - PBDT185.6532.77 467 626.87333.45 88 PBT125.2416.65 652 393.2394.74 315 NP52.119.32 459 177.2823.22 663 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Viyash Scientific to discuss resultsViyash Scientific will hold a meeting of the Board of Directors of the Company on 19 May 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Viyash Scientific consolidated net profit declines 13.83% in the December 2025 quarterNet profit of Viyash Scientific declined 13.83% to Rs 38.44 crore in the quarter ended December 2025 as against Rs 44.61 crore during the previous quarter ended December 2024. Sales rose 10.90% to Rs 858.41 crore in the quarter ended December 2025 as against Rs 774.03 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales858.41774.03 11 OPM %20.4612.89 - PBDT172.8685.76 102 PBT114.3327.37 318 NP38.4444.61 -14 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Sequent Scientific to declare Quarterly ResultsSequent Scientific will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Earnings
Sequent Scientific consolidated net profit rises 464.75% in the September 2025 quarterNet profit of Sequent Scientific rose 464.75% to Rs 14.74 crore in the quarter ended September 2025 as against Rs 2.61 crore during the previous quarter ended September 2024. Sales rose 15.01% to Rs 423.99 crore in the quarter ended September 2025 as against Rs 368.65 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales423.99368.65 15 OPM %13.1310.61 - PBDT44.3229.32 51 PBT28.8612.22 136 NP14.742.61 465 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Sequent Scientific allots 11,86,700 equity shares under ESOPSequent Scientific has allotted 11,86,700 equity shares under ESOP on 11 November 2025. Consequent to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company will increase from Rs. 50,35,25,296 consisting of 25,17,62,648 equity shares of Rs. 2 each to Rs. 50,58,98,696 consisting of 25,29,49,348 equity shares of Rs. 2 each.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Sequent Scientific to hold board meetingSequent Scientific will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 20.38%, vs industry avg of 12.48%
Over the last 5 years, market share increased from 0.49% to 0.68%
Over the last 5 years, net income has grown at a yearly rate of 13.18%, vs industry avg of 10.55%